Synaptic Imaging and Network Activity in Treatment Resistant Depression (SIGNATURE)

The study examines effects of ketamine on brain functional connectivity and the relationship between network changes and clinical response in treatment-resistant depression using MRI, EEG, cognitive testing and blood biomarkers.

A double-blind, randomized crossover design delivers three IV infusions per treatment period (ketamine 0.5 mg/kg or midazolam 0.045 mg/kg) with imaging and clinical assessments, aiming to obtain evaluable data from up to 50 subjects (actual enrolled 56).